Upload
artie
View
45
Download
0
Tags:
Embed Size (px)
DESCRIPTION
AMCo – new beginnings 20 th November 2013 . John Beighton Medical Rep/Regional Manager - Smith Kline and French UK 1981-1990 Various sales and marketing jobs – SmithKline Beecham UK 1990-1997 Commercial Director – APS Berk/ Teva UK 1997-2002 Managing Director Teva UK 2002-2009 - PowerPoint PPT Presentation
Citation preview
John Beighton
• Medical Rep/Regional Manager - Smith Kline and French UK– 1981-1990
• Various sales and marketing jobs – SmithKline Beecham UK– 1990-1997
• Commercial Director – APS Berk/Teva UK– 1997-2002
• Managing Director Teva UK– 2002-2009
• VP Global Business Optimisation – Teva Pharmaceutical Ind.– 2009 – 2010
• CEO AMCo– 2010 to date
Presenter
1991
80%
38
£106million
2012 Sales
Revenues in the United Kingdom
Countries with commercial presence
Established Brands and GenericsVirtual Business Model (R&D, Manufacturing outsourced)
------
------
------
------
------
------
------
------
------
------
Established 1991, Headquarters in South London Acquired by Cinven (Private Equity) August 2012 for £465 million
Rx
Mercury Pharma
2002
34%
100+
£109million
2012 Sales
Revenues in the United Kingdom
Countries with commercial presence
Established Brands and GenericsVirtual Business Model (R&D, Manufacturing outsourced)
------
------
------
------
------
------
------
------
------
------
Established 2002, Headquarters East of London. Acquired by Cinven (Private Equity) August 2012 for £367 million
Rx
Amdipharm
2013 Expected revenues (15% Growth)
------
------
------
------
------
------
------
------
------
------------
------
Amdipharm Mercury (AMCo)
2013
60%
112
£248million
Rx Established Brands and GenericsVirtual Business Model (R&D, Manufacturing outsourced)
Revenues in the United Kingdom
Countries with commercial presence
Combined group rebranded AMCo in March 2013UK Office to be relocated to Central London
19921999
20012004
20062007
20082013
Macrodantin, Furadantin, Macrobid, Furabid
nitrofurantoin £18m
18 Countries
figures quoted are 2013 forecast revenues
Eltroxinlevothyroxine
£27m13 Countries
Liothyronineliothyronine
£10m10 Countries
Neomercazolecarbimazole
£12m20 Countries
Fucithalmicfusidic acid
£26m>90 Countries
Hygrotonchlortalidone
£5m12 Countries
Ludiomilmaprotiline
£3m25 Countries
Cafergotergotamine
£2m26 Countries
Diamoxacetazolamide
£5m27 Countries
Hytrinterazosin
£5m21 Countries
Erythrocinerythromicin
£16m32 Countries
Akinetonbiperiden
£7m21 Countries
Transactflurbiprofen
£8m2 Countries
Acquisition History
Management Team
Guy ClarkStrategic
Development
Robert SullyGeneralCounsel
Vikram KamathFinance Director
John BeightonCEO
John CowellHuman
Resources
Bharat KarbalMedical &
Regulatory
Jane HillUK
Commercial
Karl BelkGlobal
Operations
Simon TuckerInternational Commercial
Brian McEwanManaging Director
Amdipharm
Peter van TiggelenCFO
Sales History by Company2010 to 2013 est.
2013
2012
2011
2010
£0 £50 £100 £150 £200 £250
£126
£106
£88
£79
£122
£109
£113
£125
Mercury Amdipharm
Company Performance
Millions
Top 10 Molecules (Percentage of 2012 revenue)
Levothyroxine11%
Erythromicin8%
Nitrofurantoin7%
Flurbiprofen5%
Codeine +paracetamol
5%
Biperiden4%
Liothyronine4%
Carbimazole4%
Prednisolone4%
Cyclizine3%
UK Commercial Team
Jane HillUK Commercial
Director
Jeremy DevaneyHospitals
Jenna PritchardNational Accounts
Neil CookPromoted Products
AMCo Strategy
• Focus on 5 Business Action Plans– Operational Excellence– Culture and Integration– Compliance – Quality and Reputation– International Excellence– Strategic Growth
International Excellence
AMCo offices/direct presenceDistributor networkTarget markets – direct presence
Licensing Development AcquisitionDedicated business development team focused on driving revenue and profit growth
BrandsPrimary & Secondary Care
•Low Competition•Stable Revenues and Profit•Multiple Markets•Growth Opportunities
Geographic ExpansionCompanies & Products
•Company acquisitions•Build out in Target Markets•Portfolio Optimisation•Distributor consolidation
Therapeutic FocusPrimary & Secondary Care
•Ophthalmology•Endocrinology•Urology•Infectious Diseases•Pain & Anaesthesia
Strategic Growth
Generics Primary & Secondary Care
•Low Competition•Barriers to Entry•Branded Generics•Sustainable Pricing
Strategic Development Activity• Portfolio Optimisation – registering existing AMCo products into new markets where the
product isn’t currently registered or sold, and using the existing manufacturers to make the product
• Product Development – creating new products with a contract development partner, whereby AMCo retains full ownership rights to the product, and freedom to choose who to manufacture the product
• In-Licensing – buying the rights to sell a third party’s product in a defined territory, and agreeing for the licensor to supply the product to AMCo for an agreed period of time (typically 5 years)
• Product Acquisitions – buying the permanent rights to own an existing product, in a defined territory (sometimes global e.g. Fucithalmic). The seller may wish to continue making the product, but more often would require AMCo to find a new supplier within 2-3 years
United Kingdom
No. 1 Croydon12-16 Addiscombe RoadCroydon CR0 0XT+44 (0)20 8649 8500
Committed to being a socially responsible company, we support:
Ireland
102 Block BThe Crescent BuildingNorthwood SantryDublin 9
+353 (0)1 6971640
India
101 Vedanta 779 Makwana RoadMarol Andheri East Mumbai 400 059+91 22 6678 4444
www.amcolimited.com